NKY(300109)2023-10-24 16:00Financial Performance - The company's revenue for Q3 2023 was ¥427,516,614.76, a decrease of 4.55% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2023 was ¥142,712,675.36, an increase of 8.58% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥143,405,762.13, up 7.84% from the previous year[4]. - Basic earnings per share for Q3 2023 was ¥0.45, reflecting a growth of 12.50% compared to the same period last year[4]. - Total operating revenue for Q3 2023 reached ¥1,206,530,378.32, an increase of 7.1% compared to ¥1,126,315,817.47 in Q3 2022[27]. - The total operating profit for Q3 2023 was CNY 517,205,003.67, an increase of 46.5% compared to CNY 353,097,701.28 in Q3 2022[28]. - Net profit attributable to shareholders of the parent company reached CNY 404,919,102.73, up 45.8% from CNY 277,541,195.41 in the same period last year[28]. - Total comprehensive income attributable to the parent company was CNY 406,725,711.56, compared to CNY 289,639,948.47 in the previous year, marking a 40.5% increase[29]. Cash Flow and Assets - The operating cash flow net amount for the year-to-date period reached ¥344,903,303.26, a significant increase of 275.33%[4]. - Net cash flow from operating activities surged by 275.33% to ¥344,903,303.26, driven by increased cash receipts from sales and reduced cash payments for goods[11]. - Cash flow from operating activities generated CNY 344,903,303.26, significantly higher than CNY 91,892,538.37 in Q3 2022[29]. - Cash and cash equivalents decreased to ¥310,257,433.85 from ¥544,927,993.60, a decline of 43%[23]. - The company reported a net cash outflow from investing activities of CNY 399,992,766.95, worsening from a net outflow of CNY 331,906,863.38 in Q3 2022[30]. - The net cash flow from financing activities was negative CNY 165,622,188.72, an improvement from negative CNY 417,695,215.03 in the same quarter last year[30]. - Total assets at the end of the reporting period were ¥3,970,861,647.46, representing a 6.93% increase from the end of the previous year[4]. - Non-current assets totaled ¥2,695,024,402.08, up from ¥2,280,211,969.64, indicating a growth of 18.2%[24]. Shareholder Information - Shareholders' equity attributable to the parent company increased to ¥3,459,764,862.67, a rise of 10.33% from the previous year-end[4]. - The number of ordinary shareholders at the end of the reporting period was 17,930[12]. - The top shareholder, Wang Donghu, holds 8.70% of shares, totaling 28,063,481 shares[12]. Investments and Expenses - Long-term equity investments increased by 379.38% to ¥69,001,584.83 due to increased external investments[10]. - Other non-current financial assets surged by 2505.01% to ¥103,992,000.00, attributed to increased external investments and reclassification of report items[10]. - Research and development expenses for the quarter were ¥38,650,835.34, down from ¥43,274,017.99, a decrease of 10.5%[27]. - The company invested RMB 50 million in Beijing Liangyuan Biomedical Research Co., Ltd., acquiring a 23.81% stake to enhance synergies with its cell immunotherapy products[19]. - The company invested RMB 50 million in Hangzhou Niuanjin Biotechnology Co., Ltd., obtaining an 11.11% stake to leverage collaborative effects in product development and management[19]. Liabilities and Financial Position - Total liabilities decreased to ¥535,848,419.87 from ¥596,286,950.89, a reduction of 10.1%[25]. - Accounts payable increased by 37.12% to ¥131,827,851.02 due to increased engineering and material procurement[11]. - Tax payable decreased by 49.99% to ¥54,110,829.12 primarily due to corporate income tax payments[11]. - Financial expenses decreased by 54.31% to -¥15,292,251.74, mainly due to reduced interest income and changes in exchange gains and losses[11]. - The company reported a significant decrease in leasing liabilities by 84.45% to ¥125,217.26 due to lease asset terminations[11]. Dividends and Shareholder Returns - The company distributed cash dividends of RMB 161,952,668.50 to shareholders, amounting to RMB 5.00 per 10 shares based on a total share capital of 323,905,337 as of December 31, 2022[17]. - A total of 616.75 million restricted shares from the 2021 incentive plan became eligible for release, representing 1.90% of the company's total share capital[18]. - The company granted 3 million restricted shares to its chief scientist Herbert Wilhelm Ulmer at a price of RMB 1.00 per share on February 14, 2023[16]. Future Outlook - The company plans to continue expanding its market presence and investing in new technologies and products[24].